Schmechel S C, LeVasseur R J, Yang K H-J, Koehler K M, Kussick S J, Sabath D E
Department of Laboratory Medicine, University of Washington, Seattle, WA 98195, USA.
Leukemia. 2004 Apr;18(4):841-55. doi: 10.1038/sj.leu.2403293.
Improved methods for diagnosing small B-cell lymphomas (SBCLs) and predicting patient response to therapy are likely to result from the ongoing discovery of molecular markers that better define these malignancies. In this report, we identify 120 genes whose expression patterns differed between reactive lymph node tissue and three types of SBCL: follicular lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia/small lymphocytic lymphoma. Whereas previously published studies have generally analyzed the gene expression profiles of one type of SBCL, work presented in this paper was intended to identify genes that are differentially expressed between three SBCL subtypes. This analysis was performed using mRNA pooled from multiple specimens representing each tissue type. Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was used to validate the differential expression of 23 of these genes. Among the 23 validated genes were cyclin D1 (CCND1) and B-cell CLL/lymphoma 2, which have well-known roles in lymphoma pathogenesis. The remaining 21 genes have no currently established role in lymphoma development. Using qRT-PCR, the expression of CCND1 and seven additional genes was further studied in a panel of individual specimens. Genes identified in this study are of biological interest and represent candidate diagnostic markers.
诊断小B细胞淋巴瘤(SBCL)以及预测患者对治疗反应的改进方法,很可能源于不断发现的能更好地定义这些恶性肿瘤的分子标志物。在本报告中,我们鉴定出120个基因,其在反应性淋巴结组织与三种SBCL类型(滤泡性淋巴瘤、套细胞淋巴瘤以及慢性淋巴细胞白血病/小淋巴细胞淋巴瘤)之间的表达模式存在差异。尽管此前发表的研究通常只分析了一种SBCL的基因表达谱,但本文所做的工作旨在鉴定在三种SBCL亚型之间差异表达的基因。该分析使用了从代表每种组织类型的多个标本中汇集的mRNA进行。定量逆转录聚合酶链反应(qRT-PCR)用于验证其中23个基因的差异表达。在这23个经验证的基因中,有细胞周期蛋白D1(CCND1)和B细胞淋巴瘤/白血病-2,它们在淋巴瘤发病机制中具有众所周知的作用。其余21个基因目前在淋巴瘤发展中尚未明确其作用。使用qRT-PCR,在一组个体标本中进一步研究了CCND1和另外七个基因的表达。本研究中鉴定出的基因具有生物学意义,代表了候选诊断标志物。